AbbVie: Glaucoma, Open-Angle trials

The registry lists 59 Glaucoma, Open-Angle studies with AbbVie as lead sponsor. 1 are open to participants now and 42 have results posted.

Phase 1 3Phase 2 6Phase 3 13Phase 4 14No phase 25(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With GlaucomaRecruitingNCT06822738Phase 3
• A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT04285580Phase 3Results posted
• A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT02636946Phase 3Results posted
• Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT02507687Phase 3Results posted
• Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT02250651Phase 3Results posted
• Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular HypertensionCompletedNCT02247804Phase 3Results posted
• A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular HypertensionCompletedNCT02061683Phase 4Results posted
• A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular HypertensionCompletedNCT02020512Phase 4Results posted
• A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular HypertensionCompletedNCT02003534Phase 4Results posted
• A Study of GANFORT® UD in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) in a Medical SettingCompletedNCT01999348Results posted
• Safety and Efficacy of Combigan® Ophthalmic Solution in KoreaCompletedNCT01987752Results posted
• Safety and Efficacy of Bimatoprost/Timolol (Ganfort®) Ophthalmic Solution in KoreaCompletedNCT01976624Results posted
• A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical ReasonsCompletedNCT01853085Results posted
• A Study of LUMIGAN® RC in the Clinical SettingCompletedNCT01833741Phase 4Results posted
• A Study of Bimatoprost 0.01% in the Clinical SettingCompletedNCT01814761Results posted
• A Study of Quantitative Assessments of Angle Width in Chinese Patients With Open-angle Glaucoma and/or Ocular HypertensionTerminatedNCT01781962Results posted
• An Observational Study of Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) Who Switched IOP-lowering TreatmentsCompletedNCT01735214Results posted
• A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocular HypertensionCompletedNCT01646151Results posted
• A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Were Insufficiently Responsive to MonotherapyCompletedNCT01637246Results posted
• A Study of Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)CompletedNCT01632423Results posted
• A Study of Intraocular Pressure (IOP) Reduction in Newly Diagnosed Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)CompletedNCT01628614Results posted
• GANfort® in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Are Insufficiently Responsive to MonotherapyCompletedNCT01628601Results posted
• Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)CompletedNCT01628588Results posted
• A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)CompletedNCT01594970Phase 4Results posted
• A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)CompletedNCT01589510Results posted
• Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)CompletedNCT01568008Results posted
• Safety and Efficacy of LUMIGAN® RC Versus DuoTrav® in Patients Who Require Further Intraocular Pressure (IOP) ReductionCompletedNCT01547598Phase 4Results posted
• Study Comparing Quantitative Assessments in Open-angle Glaucoma (OAG) and/or Ocular Hypertension (OHT)CompletedNCT01540370Results posted
• Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular HypertensionCompletedNCT01489670Results posted
• Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT01291108Phase 2Results posted
• Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT01253902Phase 4Results posted
• Safety and Efficacy of Bimatoprost/Timolol Fixed Combination Versus Latanoprost in Patients With Open-Angle Glaucoma Who Have Never Been TreatedCompletedNCT01243567Phase 4Results posted
• Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular HypertensionCompletedNCT01241240Phase 3Results posted
• Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular HypertensionCompletedNCT01217606Phase 3Results posted
• Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle GlaucomaCompletedNCT01215786Phase 1Results posted
• Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular HypertensionCompletedNCT01157364Phase 1/2Results posted
• Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular HypertensionCompletedNCT01110499Phase 2Results posted
• Safety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular HypertensionCompletedNCT01068964Not applicableResults posted
• Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic SolutionCompletedNCT01001195Phase 2Results posted
• Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)CompletedNCT00716742Results posted
• Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic NeuropathyCompletedNCT00693485Phase 2Results posted
• Evaluation of Hyperemia With the Use of Ocular Prostaglandin AnaloguesCompletedNCT00539526Phase 4Results posted
• 24-hour IOP-lowering Effect of Brimonidine 0.1%CompletedNCT00457795Phase 4Results posted
• A Study to Evaluate Adverse Events and Change in Disease Activity With the XEN45 Glaucoma Treatment System Implantation In Adult Participants With Open-Angle Glaucoma in ChinaActive, not recruitingNCT05821855Phase 4
• Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle GlaucomaCompletedNCT05411198Phase 3
• Expanded Access to Bimatoprost (Durysta)No longer availableNCT05338606
• 18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA)CompletedNCT04647214
• AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular HypertensionActive, not recruitingNCT04499248Phase 1/2
• Long-term Safety and Efficacy Extension Trial of Bimatoprost SRCompletedNCT03891446Phase 3
• Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT03850782Phase 3
• Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG)CompletedNCT02863705Phase 4
• Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular HypertensionCompletedNCT02571712Phase 4
• A Study of Simbrinza™ Therapy in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT02348476
• Comparison of Efficacy & Tolerability Between Ganfort vs Krytantek in Mexican Patients With Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OHT)CompletedNCT01737853
• A Study of the Rate of Progression of Glaucoma During a Follow-up Period of Two YearsCompletedNCT01629407
• Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00822055Phase 4
• Internet-based, Naturalistic Evaluation of Tolerability and Individual Patient Target Pressures With Bimatoprost 0.03% in GlaucomaCompletedNCT00487214
• Memantine in Patients With Chronic GlaucomaCompletedNCT00168350Phase 3
• Memantine in Patients With Chronic GlaucomaCompletedNCT00141882Phase 3